Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2006

View Archived Issues

FabI inhibitors shown effective against staphylococci

AN-0900's encouraging results in preclinical models of anthrax infection

ATH-18534: targets pneumonia bacterial pathogenicity

Hemispherx Biopharma reports on "excellent year"

Dusa to acquire Sirius Laboratories

Fast track designation for HuMax-EGFr in head and neck cancer

Wyeth and Trubion form strategic alliance in inflammatory disease and cancer

Bristol-Myers Squibb files sBLA for third-party manufacturing of Orencia

Sativex cleared for U.S. phase III trials

Neose Technologies cleared to study NE-180 in phase I trial

Morphotek inlicenses antibody for mesothelin-expressing cancers

Versatile topical DNA vaccine undergoes preliminary clinical study in HIV

Northfield to receive defense appropriation for PolyHeme development

Orphan drug designation for CellCept in myasthenia gravis

Ecopia BioSciences seeks clearance for phase I Canadian study of ECO-4601

Epix ramps up phase IIa study of fibrin-binding imaging agent EP-2104R

Bayer purchases GlaxoSmithKline's European telmisartan rights

Gardasil submitted for Australian approval

KW-3902 improves fluid elimination and renal function in heart failure patients

Novel agents with potential in the treatment of anxiety, depression, etc. revealed in recent patents

Climara Pro approved for prevention of postmenopausal osteoporosis

Recent patents describe possible new agents for diabetes

Phase II trial investigates iPlex for myotonic muscular dystrophy

Novel treatments for cancer subject of several recent patents

Phase II trial for NT-501 in dry AMD

Success of universal toddler Havrix(R) vaccination program in endemic hepatitis A population

Synergistic antidepressant effects seen with M-100907 and fluoxetine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...